CL2019003419A1 - Polipéptidos que antagonizan la señalización wnt en células tumorales. - Google Patents

Polipéptidos que antagonizan la señalización wnt en células tumorales.

Info

Publication number
CL2019003419A1
CL2019003419A1 CL2019003419A CL2019003419A CL2019003419A1 CL 2019003419 A1 CL2019003419 A1 CL 2019003419A1 CL 2019003419 A CL2019003419 A CL 2019003419A CL 2019003419 A CL2019003419 A CL 2019003419A CL 2019003419 A1 CL2019003419 A1 CL 2019003419A1
Authority
CL
Chile
Prior art keywords
polypeptides
tumor cells
wnt signaling
methods
antagonize wnt
Prior art date
Application number
CL2019003419A
Other languages
English (en)
Inventor
Vittoria Zinzalla
Klaus-Peter Kuenkele
Marie-Ange Buyse
Karen Cromie
Stephanie Staelens
Beatrijs Strubbe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2019003419A1 publication Critical patent/CL2019003419A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

LA INVENCIÓN PROPORCIONA POLIPÉPTIDOS DE FIJACIÓN A LRP5 NOVEDOSOS Y, MÁS ESPECÍFICAMENTE, CONSTRUCCIONES DE DOMINIO VARIABLE ÚNICO DE INMUNOGLOBULINA DE FIJACIÓN A LRP5 NOVEDOSOS, QUE PUEDEN INHIBIR LAS VÍAS DE SEÑALIZACIÓN WNT. LA INVENCIÓN TAMBIÉN SE REFIERE A SECUENCIAS ESPECÍFICAS DE ESTOS POLIPÉPTIDOS, MÉTODOS PARA SU PRODUCCIÓN Y MÉTODOS PARA USARLOS, QUE INCLUYEN MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES, TALES COMO CÁNCER.
CL2019003419A 2017-05-31 2019-11-25 Polipéptidos que antagonizan la señalización wnt en células tumorales. CL2019003419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17173782 2017-05-31

Publications (1)

Publication Number Publication Date
CL2019003419A1 true CL2019003419A1 (es) 2020-03-27

Family

ID=59021278

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003419A CL2019003419A1 (es) 2017-05-31 2019-11-25 Polipéptidos que antagonizan la señalización wnt en células tumorales.

Country Status (20)

Country Link
US (2) US11033636B2 (es)
EP (1) EP3630816B1 (es)
JP (1) JP7216024B2 (es)
KR (1) KR20200011933A (es)
CN (1) CN110637030A (es)
AR (1) AR111840A1 (es)
AU (1) AU2018276409A1 (es)
BR (1) BR112019022729A2 (es)
CA (1) CA3060401A1 (es)
CL (1) CL2019003419A1 (es)
CO (1) CO2019012329A2 (es)
EA (1) EA201992808A1 (es)
IL (1) IL270854B2 (es)
MA (1) MA48760A (es)
MX (1) MX2019014331A (es)
PE (1) PE20200610A1 (es)
PH (1) PH12019502602A1 (es)
TW (1) TW201906858A (es)
UA (1) UA125761C2 (es)
WO (1) WO2018220080A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630816B1 (en) * 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
KR20220124817A (ko) 2017-08-07 2022-09-14 더 리전트 오브 더 유니버시티 오브 캘리포니아 안전한 세포 치료제를 생성하기 위한 플랫폼
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
US11746150B2 (en) 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
EP3924381A4 (en) * 2019-02-11 2023-07-26 Surrozen Operating, Inc. MODULATION OF WNT SIGNALING IN EYE DISEASES
WO2020200998A1 (en) 2019-03-29 2020-10-08 Boehringer Ingelheim International Gmbh Anticancer combination therapy
JP2022544308A (ja) * 2019-08-14 2022-10-17 モッドマブ セラピューティクス インコーポレイテッド Ｌｒｐ５タンパク質に結合する抗体および使用方法
KR20230011226A (ko) * 2021-07-13 2023-01-20 인제대학교 산학협력단 NEURL 유전자, 이를 포함하는 발현벡터 또는 NEURL 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물
WO2023019137A1 (en) * 2021-08-10 2023-02-16 Heat Biologics, Inc. Generation and characterization of novel tim-4 binding agents
CN114702588B (zh) * 2022-04-27 2022-11-22 博际生物医药科技(杭州)有限公司 抗Nectin-4抗体和双特异性抗体
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU733722B2 (en) 1997-04-15 2001-05-24 Merck Sharp & Dohme Corp. Novel LDL-receptor
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2405912A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
CA2446582A1 (en) 2001-05-17 2002-11-21 Genome Therapeutics Corporation Reagents and methods for modulating dkk-mediated interactions
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
EP1814917A2 (en) 2004-10-13 2007-08-08 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
WO2007027509A2 (en) * 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
DE112009000507T5 (de) 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
MX2012005345A (es) 2009-12-23 2012-06-08 Esbatech Alcon Biomed Res Unit Metodo para disminuir inmunogenicidad.
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
JP5826194B2 (ja) 2010-03-03 2015-12-02 アブリンクス ナームローゼ フェンノートシャップ 二パラトープ性ａ−ベータ結合ポリペプチド
NZ602040A (en) * 2010-03-24 2014-12-24 Genentech Inc Anti-lrp6 antibodies
AU2011249782B2 (en) 2010-05-06 2014-10-02 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
KR20140035337A (ko) * 2011-01-28 2014-03-21 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Ｗｎｔ 조성물 및 이의 사용 방법
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
IL229503B (en) 2011-06-23 2022-06-01 Ablynx Nv Techniques for predicting, detecting and reducing interference of a-specific protein in tests involving single variable domains of immunoglobulin
KR102143506B1 (ko) 2011-08-17 2020-08-12 글락소 그룹 리미티드 변형된 단백질 및 펩티드
EP2773669B1 (en) 2011-11-04 2018-03-28 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
IN2014DN05885A (es) 2012-01-18 2015-06-05 Hoffmann La Roche
JP7046804B2 (ja) 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
ES2821099T3 (es) * 2015-12-04 2021-04-23 Boehringer Ingelheim Int Gmbh & Co Kg Polipéptidos biparatópicos antagonistas de la señalización WNT en células tumorales
EP3630816B1 (en) * 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
WO2020200998A1 (en) * 2019-03-29 2020-10-08 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Also Published As

Publication number Publication date
PH12019502602A1 (en) 2020-06-08
US11033636B2 (en) 2021-06-15
EA201992808A1 (ru) 2020-05-14
JP7216024B2 (ja) 2023-01-31
JP2020521478A (ja) 2020-07-27
PE20200610A1 (es) 2020-03-10
IL270854A (en) 2020-01-30
US20220362393A1 (en) 2022-11-17
IL270854B (en) 2022-10-01
KR20200011933A (ko) 2020-02-04
EP3630816A1 (en) 2020-04-08
IL270854B2 (en) 2023-02-01
WO2018220080A1 (en) 2018-12-06
MA48760A (fr) 2020-04-08
MX2019014331A (es) 2020-01-27
TW201906858A (zh) 2019-02-16
CA3060401A1 (en) 2018-12-06
US20180344868A1 (en) 2018-12-06
AU2018276409A1 (en) 2019-10-31
CN110637030A (zh) 2019-12-31
UA125761C2 (uk) 2022-06-01
BR112019022729A2 (pt) 2020-05-19
CO2019012329A2 (es) 2020-01-17
AR111840A1 (es) 2019-08-21
EP3630816B1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
CL2019003419A1 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales.
CO2018005680A2 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
CY1122415T1 (el) Κυκλοπροπυλαμινες ως lsd1 αναστολεις
CY1122314T1 (el) Κυκλοπροπυλαμινες ως αναστολεις lsd1
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CL2019002461A1 (es) Arn terapéutico.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MD3582853T2 (ro) Compuși di-nucleotidici ciclici pentru tratamentul cancerului
CO2017011484A2 (es) Inhibidores de bromodominio
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201592005A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
UY37018A (es) Inhibidores bicíclicos de pad4
EA201691725A1 (ru) Соединения для лечения опосредованных комплементом нарушений
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
CY1123031T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
CL2018001652A1 (es) Composiciones y métodos para disminuir la expresión de tau
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
UY37017A (es) Inhibidores aza-bencimidazol de pad4
AR120223A1 (es) Proteínas que unen nkg2d, cd16 y flt3